

CONTENTS

Sponsors 3

Steering Committee..... 4

Conference Program

- Agenda 5
- Event Details..... 6

Upcoming BIO Events..... 27



Partnering for
Global Health Forum 2011

SPONSORS

BIO and BVGH thank the following sponsors, without whose support this conference would not be possible.

DOUBLE HELIX SPONSOR



GOLD SPONSORS



SILVER SPONSOR



STEERING COMMITTEE

BVGH and BIO would like to offer special thanks to the members of the Steering Committee for their efforts in making the Partnering for Global Health Forum 2011 a success.

Margaret Anderson, Executive Director, *FasterCures*

Rashmi Barbhuiya, CEO and Managing Director, Advinus Therapeutics

Seth Berkley, President & CEO, International AIDS Vaccine Initiative

G. Steven Burrill, CEO, Burrill & Company

Lisa Conte, CEO, Napo Pharmaceuticals

Mark Feinberg, Vice President of Medical Affairs and Policy, Merck Vaccines

Carl Feldbaum, Chairman, BIO Ventures for Global Health

Maria C. Freire, President, Lasker Foundation

James C. Greenwood, President & CEO, Biotechnology Industry Organization

Paul Klingenstein, Managing Partner, Aberdare Ventures

Anthony P. Lakavage, Worldwide Vice President, Public Affairs, BD

Mary Moran, Director, Policy Cures

Melinda Moree, CEO, BIO Ventures for Global Health

Bernard Pécoul, Executive Director, Drugs for Neglected Diseases *initiative*

David Perry, CEO, Anacor Pharmaceuticals

Regina Rabinovich, Director, Infectious Diseases Program, Bill & Melinda Gates Foundation

Una Ryan, CEO, Diagnostics for All

Peter Singer, CEO, Grand Challenges Canada

Hassan Mshinda, Director General, Tanzania Commission for Science and Technology

AGENDA

Current as of Thursday, June 16, 2011. Schedule subject to change. Please see daily schedules posted in corridors and/or handouts for late additions or revisions.

MONDAY, JUNE 27

7:30 AM–8:15 AM	NETWORKING BREAKFAST	Rooms 146B & 146C
8:30 AM–8:45 AM	OPENING REMARKS	Room 146A
8:45 AM–9:45 AM	PANEL 1: Knowing is Half the Battle: Parsing the Global Health Value Chain	Room 146A
10:00 AM–11:00 AM	BREAKOUT SESSIONS: NEW PRODUCT INTRODUCTION	
	IA Therapeutic Drugs	Room 146B & 146C
	IB Vaccines	Room 146A
	IC Diagnostics	Room 156
11:15 AM–12:15 PM	PANEL 2: Blueprint for the Future: Exploring R&D Incentives	Room 146A
12:30 PM–1:30 PM	NETWORKING LUNCH Sponsored by MERCK	Room 146B & 146C
1:45 PM–2:45 PM	PANEL 3: Accounting for Global Health: Understanding Funding Opportunities	Room 146A
3:00 PM–4:00 PM	BREAKOUT SESSIONS	
	3A How to Access Non-Traditional Financing	Room 156
	3B Strategies for Engaging Emerging Markets	Room 146A
4:15 PM–5:15 PM	KEYNOTE ADDRESS Francis Collins, Director, National Institutes of Health	Room 146A
5:15 PM–5:30 PM	CLOSING REMARKS	Room 146A
5:30 PM–7:00 PM	NETWORKING COCKTAIL RECEPTION	Room 146B

TUESDAY, JUNE 28*

8:00 AM–5:00 PM	PARTNERING AT THE BUSINESS FORUM
9:00 AM–11:00 AM	COMPANY PRESENTATIONS AT THE BUSINESS FORUM
2:00 PM–4:00 PM	COMPANY PRESENTATIONS AT THE BUSINESS FORUM

WEDNESDAY, JUNE 29*

8:00 AM–5:00 PM	PARTNERING AT THE BUSINESS FORUM
9:00 AM–11:00 AM	COMPANY PRESENTATIONS AT THE BUSINESS FORUM
2:00 PM–4:00 PM	COMPANY PRESENTATIONS AT THE BUSINESS FORUM

THURSDAY, JUNE 30*

8:00 AM–5:00 PM	PARTNERING AT THE BUSINESS FORUM
9:00 AM–11:00 AM	COMPANY PRESENTATIONS AT THE BUSINESS FORUM
1:00 PM–3:00 PM	COMPANY PRESENTATIONS AT THE BUSINESS FORUM

*Partnering and Company Presentations will take place at the Business Forum in Hall D on Level 2 of the Walter E. Washington Convention Center.

PANEL I

Knowing is Half the Battle: Parsing the Global Health Value Chain

MODERATOR:

- Susan Dentzer, Editor, Health Affairs

PANELISTS:

- Hassan Mshinda, Director General, Commission for Science and Technology, Tanzania
- Regina Rabinovich, Director, Infectious Diseases Program, Bill & Melinda Gates Foundation
- Rajiv Shah, Administrator, USAID

WHO'S WHO

Susan Dentzer is the Editor-in-Chief of Health Affairs, the nation's leading journal of health policy, and is an on-air analyst on health issues with the PBS NewsHour. She previously led the NewsHour's health unit, reporting extensively on-air about health care reform debates. She is an elected member of the Institute of Medicine and the Council on Foreign Relations. Ms. Dentzer graduated from Dartmouth, is a trustee emerita of the college, and chaired the Dartmouth Board of Trustees from 2001 to 2004. She currently serves as a member of the Board of Overseers of Dartmouth Medical School and is an Overseer of the International Rescue Committee, a leading humanitarian organization. She is also on the board of directors of Research!America, an alliance working to make research to improve health a higher priority.

Hassan Mshinda, PhD, is the Director General of Tanzania Commission for Science and Technology in Tanzania. He completed his Master's of Science in Applied Parasitology and Medical Technology at the University of Liverpool and PhD in Epidemiology at the University of Basel in Switzerland. Dr. Mshinda has led several research projects funded by Multilateral Initiative of Malaria in Africa, Swiss Agency for Development and Cooperation, International Atomic Energy Agency, International Development Research Centre in Canada, European Union, Ireland Aid and Novartis Foundation for Sustainable Development. He has published several papers in communicable disease and health system.

Dr. Mshinda has conducted several international and national consultancies assigned by Department of International Development, Danish Development Agency and World Health Organization. Global Fund for HIV/AIDS, TB and Malaria.

Regina Rabinovich is Director of the Global Health Program's Infectious Diseases Development team. She oversees the development and implementation of strategies for the prevention, treatment, and control of diseases of particular relevance to global health, including malaria, pneumonia, diarrhea, and neglected diseases.

Prior to joining the foundation, Dr. Rabinovich served in various positions at the U.S. National Institute of Allergy and Infectious Diseases (NIAID), focusing on the development and evaluation of vaccines. She participated in the Children's Vaccine Initiative, a global effort to prevent infectious diseases in children in the developing world, and served as liaison to the National Vaccine Program Office, focusing on vaccine safety and vaccine research. As chief of the Clinical and Regulatory Affairs Branch of the Division of Microbiology and Infectious Diseases, she managed the evaluation of

candidate vaccines through a network of U.S. clinical research units. During her tenure as branch chief, the units completed large multi-center trials of pertussis and influenza vaccines as well as a number of phase I trials of platform technologies, such as an edible vaccine and vaccines for malaria and rotavirus.

In 1999, Dr. Rabinovich became director of the PATH Malaria Vaccine Initiative, a project funded by the foundation to advance efforts to develop promising malaria vaccine candidates. She serves on the boards of several organizations focused on global health and infectious diseases, including the Global Fund for AIDS, TB & Malaria; the NIAID Council; Medicines for Malaria Venture; PATH Vaccine Solutions; and the Institute of OneWorld Health.

Dr. Rabinovich received her medical degree from Southern Illinois University and her Master of Public Health degree from the University of North Carolina in Chapel Hill. She joined NIAID's Epidemiology Training Program as a fellow in 1988.

Rajiv Shah was sworn in as the 16th Administrator of the United States Agency for International Development (USAID) on December 31, 2009. USAID, a U.S. Government agency, has provided economic and humanitarian assistance worldwide for almost 50 years.

Previously, Dr. Shah served as Under Secretary for Research, Education and Economics and as Chief Scientist at the U.S. Department of Agriculture, where he was responsible for safe, sustainable, competitive U.S. food and fiber system, as well as strong communities, families, and youth through integrated research, analysis, and education. At USDA, he launched the National Institute of Food and Agriculture, a new scientific institute that elevated the status and funding of agricultural research to be more in line with other major scientific groups. He also produced innovative initiatives in bio-energy, climate, global food security, childhood obesity, and food safety.

Prior to joining the Obama Administration, Shah served as director of Agricultural Development in the Global Development Program at the Bill & Melinda Gates Foundation. In his seven years with the Gates Foundation, Shah served as the Foundation's director of Strategic Opportunities and as deputy director of policy and finance for the Global Health Program. In these roles, he helped develop and launch the foundation's Global Development Program, and helped create both the Alliance for a Green Revolution in Africa, and the International Finance Facility for Immunization-an effort that raised more than \$5 billion for child immunization.

Prior to joining the Gates Foundation in 2001, Shah was the health care policy advisor on the Gore 2000 presidential campaign and a member of Pennsylvania Gov. Ed Rendell's transition committee on health. He is the co-founder of Health Systems Analytics and Project IMPACT for South Asian Americans. In addition, he has served as a policy aide in the British Parliament and worked at the World Health Organization.

Originally from Detroit, Michigan, Shah earned his MD from the University of Pennsylvania Medical School and his Master of Science in health economics at the Wharton School of Business. He has attended the London School of Economics, is a graduate of the University of Michigan, and has published articles on health policy and global development. Shah previously served on the boards of the Alliance for a Green Revolution in Africa (AGRA), the Seattle Public Library, and the Seattle Community College District. In 2007, he was named a Young Global Leader by the World Economic Forum.

Dr. Shah is married with three children. He lives in Washington, D.C.

BREAKOUT SESSION 1A NEW PRODUCT INTRODUCTION

Following Panel 1, there will be three separate breakout sessions. Each of these will explore strategies for the introduction of new interventions to developing world markets—one focusing on drugs, one on vaccines and one on diagnostics. Panelists with on-the-ground experience will discuss key barriers to effective product introduction and key interventions at both the global and local levels to overcome these hurdles.

Therapeutic Drugs

MODERATOR:

- Wendy Woods, Partner and Managing Director, Boston Consulting Group

PANELISTS:

- Geoffroy DeCarbonnel, Principal, Global Public Sector, PRTM
- James A. Geraghty, Senior Vice President, Genzyme Corporation
- Bernard Pécoul, CEO, Drugs for Neglected Diseases *initiative*
- Inder Singh, Executive Vice President, Drug Access Programs, Clinton Foundation Health Access Initiative (CHAI)

WHO'S WHO

Geoffroy DeCarbonnel is a Principal in PRTM's Global Public Sector practice. He co-leads PRTM's work in Global Health and Development. He is currently based in Washington, DC, and has lived and worked in Europe, Africa and Asia.

At PRTM, Geoffroy works with not-for-profit and non-governmental organizations, government and commercial clients to develop their operational strategy and the capabilities necessary to achieve their mission. In helping these organizations, his work has included evaluation of public-private partnerships, design and implementation of planning processes, and supply chain strategy development. In Global Health and Development, he has focused on challenges and opportunities in global and local supply chains to improve efficient and effective delivery of product to patients, working both with international and in-country organizations. He has worked most recently on HIV, Tuberculosis and Malaria.

Prior to PRTM, Geoffroy worked in industry where he was responsible for global supply chain and logistics, and in consulting where he worked on strategy development and operational management projects. Through these assignments, Geoffroy has lived in Europe and Africa. Geoffroy earned a BScE in Aerospace Engineering from Princeton University and an MS in Industrial Administration from Carnegie Mellon University.

James A. Geraghty joined Genzyme in 1992. He is responsible for corporate development, product acquisition and partnering transactions. He led Genzyme's recent licensing deal with Isis Pharmaceuticals and the acquisition of SangStat Medical Corporation in 2003. He oversaw the commercialization of Cholestagel in Europe and has served as president of Genzyme Europe.

Prior to joining Genzyme, Mr. Geraghty was vice president of marketing and strategic planning for Baxter/Caremark International. He has also worked as a consultant on international health care strategy at Bain and Company.

Mr. Geraghty has a JD from Yale Law School, an MS from the University of Pennsylvania and a B.A. from Georgetown University.

Bernard Pécoul has led DNDi since its founding in 2003. DNDi and its partners have built the largest and most robust R&D portfolio for three of the most neglected diseases (leishmaniasis, Human African Trypanosomiasis or sleeping sickness, and Chagas disease), launched ASAQ and ASMQ, two low-cost, non-patented antimalarial combinations, and NECT, the first new treatment against sleeping sickness in 25 years. Prior to DNDi, Bernard Pécoul was director of Médecins Sans Frontières (MSF)-Access Campaign and as such played a key role in the creation of DNDi. Before that, he was the Executive Director of MSF-France, acted as a co-founder of Epicentre, and worked as a MSF field physician in Africa, Latin America, and Asia. Bernard Pécoul obtained his Doctorate in Medicine from the University of Clermont Ferrand in France and his Master of Public Health from Tulane University in the USA.

Inder Singh is the Executive Vice President of Access Programs at the Clinton Health Access Initiative (CHAI). He oversees a group of 45 business professionals and scientists, and a portfolio of initiatives to enable greater access to medicines and diagnostics. He and his team have negotiated a series of agreements with pharmaceutical companies that lowered the price of drugs for HIV/AIDS, malaria, and tuberculosis by up to 80 percent for 74 developing country governments, the World Health Organization, and the Global Fund to Fight AIDS, Malaria and Tuberculosis, leading to over \$1 billion in cost savings. An estimated 3.6 million HIV/AIDS patients and over 30 million people suffering from malaria to benefit from these agreements.

Inder's group deploys technical and management capabilities to strengthen health systems, and utilizes a market-based approach to lower prices, enhance quality, or accelerate the entry of new improved medical products. For example, by working with suppliers to reduce their costs of production, commercial risks, or the investment required to develop a product, pharmaceutical companies are willing to commit to lower prices or more rapid product development.

During the course of his work at CHAI, Inder has traveled to more than 25 countries, and has advised eight governments. Prior to joining CHAI, Inder worked in consulting and at a series of startup companies in the information technology and medical industries. Inder is also the founder of a successful nonprofit organization that supports children undergoing extensive physical rehabilitation.

Inder is a magna cum laude graduate of the University of Michigan School of Engineering and holds three graduate degrees in business administration, public policy and biomedical enterprise from MIT's Sloan School of Management, Harvard's Kennedy School of Government, and the Harvard-MIT Division of Health Science and Technology. He is a third degree black belt in the martial arts, enjoys scuba diving, playing strategy games especially chess and poker, and dancing.

Wendy Woods is a Partner and Managing Director of the Boston Consulting Group. She leads BCG's work in global public health, and also works with bio-pharmaceutical clients. She is currently based in BCG's Boston office, and has worked across Europe, Asia and Africa.

In leading BCG's global public health efforts, Wendy works with foundations, public private partnerships and multilateral organizations. With these organizations, she has helped to develop

strategies, create public private partnerships, improve their operational effectiveness and improve approaches to deliver health interventions. She has worked on HIV, TB, malaria, diarrheal disease, pneumonia and oncology issues and across drugs, vaccines and diagnostics.

In biopharmaceuticals, her work has included re-designing decision making structures, processes and operations across R&D and Commercial organizations, creating market and competitive strategies for therapeutics, and developing R&D portfolio management strategies and processes.

Before joining BCG, Wendy worked for the Organization for Economic Cooperation and Development in Paris, where she evaluated and analyzed global trends in international trade, investment, employment, R&D and structural change across industries. She also worked as a Senior Economist for the U.S. Bureau of Labor Statistics. Wendy earned an AB in economics from the University of Michigan and an MBA from the J.L. Kellogg Graduate School of Management at Northwestern University.

BREAKOUT SESSION 1B

NEW PRODUCT INTRODUCTION

Following Panel 1, there will be three separate breakout sessions. Each of these will explore strategies for the introduction of new interventions to developing world markets—one focusing on drugs, one on vaccines and one on diagnostics. Panelists with on-the-ground experience will discuss key barriers to effective product introduction and key interventions at both the global and local levels to overcome these hurdles.

Vaccines

MODERATOR:

- Carol Marzetta, Chief Scientific Officer, Applied Strategies

PANELISTS:

- Mark Feinberg, Vice President, Medical Affairs and Policy, Merck Vaccines
- Philip Hosbach, Vice President, Government Relations and Immunization Policy, Sanofi Pasteur
- Fred Were, Chairman, Kenya Pediatric Association

WHO'S WHO

Mark Feinberg is Vice President for Medical Affairs and Policy for Merck Vaccines and Infectious Diseases where he focuses on global efforts to implement vaccines and infectious disease therapies to achieve the greatest individual and public health benefits. In this role, he is also responsible for developing initiatives and partnerships that accelerate the global availability of Merck's drugs and vaccines, and that enable Merck's R&D expertise to help address health challenges impacting resource-poor countries. Prior to joining Merck in 2004, Dr. Feinberg worked for over 20 years in both academia and government where he was actively engaged in basic and clinical research, patient care and health care policy—awith a primary focus on HIV/AIDS pathogenesis, treatment and prevention research. Dr. Feinberg is a Fellow of the American College of Physicians, and a member of the Council on Foreign Relations and the Association of American Physicians. He is the recipient of an Elizabeth Glaser Scientist Award from the Pediatric AIDS Foundation and an Innovation in Clinical Research Award from the Doris Duke Charitable Foundation. Dr. Feinberg also currently serves as a member of the National Vaccine Advisory Committee, the Institute of Medicine's Forum on Microbial Threats, the External Advisory Board of the HIV Vaccine Trials Network, the Board of Directors of the African Comprehensive HIV/AIDS Partnerships, and the Board of Trustees of the National Foundation for Infectious Diseases.

Philip Hosbach currently holds the position of Vice President of Immunization Policy and Government Relations at Sanofi Pasteur. The departments under his supervision are state government affairs, federal government affairs, medical communications, strategic advocacy and immunization initiatives. His responsibilities include oversight of both public policy and immunization policy development. Mr. Hosbach acts as Sanofi Pasteur's principle liaison with CDC, and coordinated Sanofi Pasteur's global efforts in responding to the emerging H1N1 pandemic.

He is a graduate of Lafayette College (1984) and began his professional career in the pharmaceutical industry with American Home Products.

That career has now spanned 27 years, including the last 24 years focused solely on vaccines. Mr. Hosbach joined Sanofi Pasteur (then Connaught Labs) in 1987 in Clinical Research and held positions of increasing responsibility, including Director of Clinical Operations. While in Clinical Research, he also served as Project Manager for the development and licensure of Tripedia, the first diphtheria, tetanus and acellular pertussis (DTaP) vaccine approved by FDA for use in US infants. During his clinical research career at Sanofi Pasteur, he contributed to the development and licensure of seven vaccines.

Following his work in clinical research Mr. Hosbach took a position in the commercial operations area of Sanofi Pasteur and took on positions of increasing responsibility on the business administration side of the vaccine division. During that time Mr. Hosbach led a number of departments within Sanofi Pasteur gaining valuable business experience within US Commercial Operations. The departments he led during that time included Public Health Sales and Marketing, Public Relations, Public Affairs, New Product Marketing and Business Intelligence.

Carol Marzetta is Chief Scientific Officer and co-founder of Applied Strategies, a management consulting firm dedicated to bridging the discoveries of life sciences and the needs of global health.

She has been integral to the company's work in helping the global health community forecast vaccine supply and demand, assess the value and risk to suppliers and donors of global markets, and understand the potential impact of new product introduction, both individually and across a portfolio of new products and interventions. She has led projects assessing new technology critical path and health impact, conducting global market characterization and value assessments, and supporting public-private partnerships.

Dr. Marzetta has over 15 years of leadership experience in small molecule and biologic drug development in both global pharmaceutical and emerging biotechnology companies and over eight years in global health. Her broad experience spans drug discovery, preclinical and clinical development. She now brings her global biopharmaceutical and global health experience together to find solutions that bring private industry and global health partners together to accelerate the introduction of medicines and vaccines into developing countries.

Fred Were is a pediatrician and specialist in neonatal medicine. Dr. Were became the National Chairman of the Kenya Pediatric Association (KPA), an affiliate of the International Pediatric Association, in 2003 and holds the position to date. He has overseen the transformation of KPA into a public health-focused group. The association is currently involved in the national pediatric HIV/AIDS care project and interventions for improving newborn survival at the community level. He is also Associate Professor of newborn medicine at the University of Nairobi and Aga Khan University (Nairobi). He joined the University of Nairobi in 1994, where he still serves as a senior lecturer in the Department of Pediatrics.

Dr. Were was the principal investigator of a PneumoADIP small grants project aimed at enhancing health worker and health administrator awareness of pneumococcal disease and vaccination in Kenya. Dr. Were is a recognized expert in pediatrics and has written extensively on newborn health.

BREAKOUT SESSION 1C NEW PRODUCT INTRODUCTION

Following Panel 1, there will be three separate breakout sessions. Each of these will explore strategies for the introduction of new interventions to developing world markets—one focusing on drugs, one on vaccines and one on diagnostics. Panelists with on-the-ground experience will discuss key barriers to effective product introduction and key interventions at both the global and local levels to overcome these hurdles.

Diagnostics

MODERATOR:

- Maurine Murtagh, CEO, The Murtagh Group

PANELISTS:

- Andrew Fish, Executive Director, AdvaMed Dx
- Gonzalo Domingo, Senior Scientist, PATH
- Lauren Mikulski, Strategic Project Manager, Global Health, BD
- Trevor Peter, Senior Laboratory Specialist, Clinton Foundation Health Access Initiative (CHAI)

WHO'S WHO

Gonzalo Domingo currently serves as the senior technical lead for several diagnostics development projects at PATH including the development of point-of-care rapid diagnostic tests. He manages complex collaborations involving public-sector organizations, diagnostic technology companies, reagent suppliers, contract manufacturing facilities, and other research institutions. Gonzalo has extensive expertise in parasitology research and field-based experience using diagnostic technologies in low-resource settings. Gonzalo is co-principal investigator of the GHDx Center, where he leads activities aimed at encouraging early exploratory research into innovative approaches in the development of diagnostics for low-resource settings. He established a rigorous review process to identify and evaluate emerging technologies, and he manages a grant-making mechanism with a total budget of \$1 million. He is also involved in designing, coordinating, performing, and managing evaluations and studies of diagnostic tests to assess their performance in the lab and field. He is skilled at clinical sample processing, diagnostic test development and parasitology research. Dr. Domingo's previous experience includes supervision of a clinical laboratory and teaching undergraduate and graduate programs.

Andrew Fish is Executive Director of AdvaMedDx, representing leading manufacturers of in vitro diagnostic tests. Functioning as an association within AdvaMed, the medical device trade association, AdvaMedDx advocates for health care policies that support robust innovation, ensure timely approval, and promote rapid adoption of new, safe and effective in vitro diagnostic tests.

Andy has extensive government relations, legal, regulatory, and policy background in food, drug, health, and agriculture issues. Andy was previously Senior Vice President of Legal and Government Affairs, General Counsel, and Secretary for the Consumer Healthcare Products Association (CHPA), representing manufacturers of nonprescription medicines and dietary supplements. Andy also worked for the American Cancer Society as Senior Director of Federal Government Relations.

Earlier in his career, Andy served as Assistant Secretary of Agriculture for Congressional and Intergovernmental Affairs, after twice working for the U.S. Senate Agriculture Committee, first as a professional staff member and later as deputy chief counsel. Andy's work in private practice focused on biotech regulation, as well as on a wide range of food, drug and agriculture issues. Andy is a graduate of Yale University and Stanford Law School.

Lauren Mikulski joined BD (Becton, Dickinson & Co.) in 2009, and serves as Strategic Manager for Global Health. In this role she is responsible for evaluating new technologies for resource-limited settings that will increase access to quality healthcare for patients in developing countries and emerging markets. She develops Global Health's long-term strategy and manages BD's global public-private partnerships to identify new opportunities to advance global health around the world.

In her current role based in Nairobi, Kenya, she leads BD's future efforts for go-to-market strategies and sustainability for diagnostics in developing countries. Her role allows her to work across BD's three business segments and travel to locations worldwide to determine which technologies and programs can help advance BD's strategic innovation initiatives.

Prior to her current role at BD, Lauren worked at Johnson & Johnson, (Tibotec Therapeutics), Dell Inc., Cayuga Medical Center, Rockefeller University, and Africare where she lived and worked in Uganda. Lauren has been involved in the fight against HIV/AIDS for over 10 years and has been dedicated to helping expand access to healthcare and medical technology. Lauren holds an MBA with majors in Health Enterprise Management, Marketing, International Business, Management & Strategy, and Social Enterprise from Kellogg School of Management at Northwestern University in Evanston, IL. She also holds a Bachelor of Science degree in Industrial & Labor Relations with a concentration in Law & Society from Cornell University in Ithaca, NY.

Maurine Murtagh is currently a consultant on diagnostics in resource-limited settings in which capacity she is working with the Bill & Melinda Gates Foundation and UNITAID. Until recently, Maurine was the Director of Diagnostic Services for the Clinton Health Access Initiative (CHAI), a position she held for about five years. Prior to joining CHAI, Maurine was a corporate partner at the law firm of Howard Rice Nemerovski Canady Falk & Rabkin in San Francisco, California, where her focus was on mergers and acquisitions and securities law. Maurine began her career in investment banking, where she worked for both Smith Barney and Morgan Stanley. She graduated from Georgetown University and holds an MBA from the University of Texas at Austin, an M.Phil. in finance from Columbia University and a JD from Duke University.

Trevor Peter, PhD, MPH, Scientific Director for Laboratory Services at the Clinton Health Access Initiative (CHAI), has spent the past 15 years in diagnostics, research and public health. He presently leads a team providing technical assistance on the cost-effective development and deployment of diagnostics capacity, particularly for HIV, TB and malaria. He has advised governments of over 30 countries across Africa, Asia, and the Caribbean on scaling up diagnostics, introducing new technology and strengthening laboratory systems.

Before joining CHAI, he was laboratory director at Botswana-Harvard HIV Reference Laboratory, and before this led a USAID-supported vector-borne disease epidemiology research program in Zimbabwe. Dr. Peter sits on the boards of directors of the African Society for Laboratory Medicine, which is based in Addis Ababa, and the African Center for International Laboratory Training in Johannesburg, South Africa. He is also on the Steering Committee of the WHO-AFRO Laboratory Accreditation program.

PANEL 2

Blueprint for the Future: Exploring R&D Incentives

This panel will frame the need for mechanisms, complementary to grant funding, that engage industry in global health research and development. Panelists will explore lessons learned from both past and ongoing research and development (R&D) incentive design efforts (the Advance Market Commitment, the efforts of the WHO Expert Working Group and others) and discuss how this knowledge can help in designing future R&D incentives.

MODERATOR:

- Robert Hecht, Managing Director, Results for Development

PANELISTS:

- Margaret Anderson, Executive Director, *FasterCures*
- Donald R. Joseph, COO, BIO Ventures for Global Health
- Orin Levine, Executive Director, International Vaccine Access Center (IVAC)
- Jaykumar Menon, Senior Director, Education and Global Development, X Prize Foundation

WHO'S WHO

Margaret Anderson is Executive Director of FasterCures/The Center for Accelerating Medical Solutions, an “action tank” working to improve the medical research system – to speed up the time it takes to get important new medicines from discovery to patients. She defines the organization’s strategic priorities and positions on key issues, develops its programmatic portfolio, and manages its operations. In her role, she helps bring sectors together to facilitate collaboration, and ensures policies are in place to promote medical progress. In 2011, the Clinical Research Forum recognized her with an award for leadership in public advocacy, a testament to the positive impact of her leadership and FasterCures’ vital role in improving the medical research system. She is Vice President of the Alliance for a Stronger FDA, and co-chairs the eHealth Initiative’s Council on Data and Research. She also is board member of the Council for American Medical Innovation, the Coalition for the Advancement of Medical Research, the Prostate Cancer Foundation Government Affairs Committee, and the Institute of Medicine’s Forum on Drug Discovery, Development and Translation.

Robert Hecht joined the Results for Development as a Managing Director in April 2008, concurrent with the establishment of the new Institute. He oversees a portfolio of projects analyzing policy barriers and proposing solutions related to AIDS and vaccine financing, health financing reforms to help countries move toward universal coverage, and improving research and development and access to new health technologies in developing countries.

Before coming to Results for Development, Dr. Hecht spent four years as Senior Vice President for Policy and Advocacy at the International AIDS Vaccine Initiative. Prior to this, he had a 20-year tenure at the World Bank, where he occupied a number of senior posts including head of the Bank's central unit for Health, Nutrition, and Population, with oversight for global strategies, knowledge management, technical services, and partnerships; Chief of Operations for the Human Development Network; principal economist in the Latin America region; and member of the core team and a lead

author of the 1993 World Development Report, "Investing in Health." From 1987 to 1996, Dr. Hecht was responsible for World Bank sponsored studies and projects in health, nutrition, and education in Africa and Latin America.

Dr. Hecht served as a director of the Joint United Nations Program on HIV/AIDS (UNAIDS) from 1998 to 2001, where he managed technical units based in South Africa, Cote d'Ivoire, and Thailand, and in Geneva. He led UNAIDS efforts to present AIDS as a development and poverty issue impacting a wide range of social and economic goals and to analyze financing patterns, needs and modalities for fighting the pandemic.

Dr. Hecht is the author of more than 40 articles, book chapters, and other publications. He received his undergraduate degree from Yale College and his doctorate from Cambridge University.

Donald R. Joseph was named Chief Operating Officer (COO) for BIO Ventures for Global Health (BVGH) in April 2010. Mr. Joseph brings to the organization a wealth of experience in the biopharmaceutical industry. Before joining BVGH, he served in senior executive positions in both legal and business roles at private and publicly held biopharmaceutical companies including Renovis and Abgenix, where he played a key role in its acquisition by Amgen. He has consulted for a number of biopharmaceutical companies and previously served as COO of the Institute for OneWorld Health, a non-profit pharmaceutical company devoted to developing new and affordable medicines for neglected diseases.

Mr. Joseph has extensive business and legal experience, with more than 15 years in the biopharmaceutical industry. His industry projects have included a wide array of commercial, mergers and acquisitions, licensing, collaboration, and financing transactions, while providing business guidance for R&D, product launches, and sales and marketing. His therapeutic areas of experience include neurology, oncology, and antibody technology, as well as malaria and infectious diseases. His operations experience includes involvement with many marketed products in addition to research, preclinical, and clinical development of a number of products and technologies.

Prior to entering the biopharmaceutical industry, Mr. Joseph was an international partner in the San Francisco/Palo Alto office of Baker & McKenzie. He received his JD from the University of Texas Law School.

Orin S. Levine, PhD, is an Associate Professor in the Department of International Health, Johns Hopkins Bloomberg School of Public Health, and Executive Director of the International Vaccine Access Center. Dr. Levine received his undergraduate degree from Gettysburg College, and his PhD in Epidemiology from Johns Hopkins Bloomberg School of Public Health. He is an epidemiologist, trained in control and prevention of infectious diseases, especially respiratory infections in developing countries. For over 15 years Dr. Levine has worked on efforts to accelerate the development, evaluation and introduction of new vaccines against Haemophilus influenza type B and Streptococcus pneumoniae into routine immunization programs in developing countries. The International Vaccine Access Center aims to accelerate access to vaccines for children everywhere, through evidence-driven policy making.

Dr. Levine is also Director for Special Studies, AVI-TAC (Accelerated Vaccine Initiative-Technical Assistance Consortium), which is funded by the GAVI Alliance works to build evidence to support the use of new vaccines in GAVI-eligible countries. Dr. Levine also serves as P.I. of the Gates Foundation funded PERCH (Pneumonia Etiology Research for Child Health) project, which aims to prepare the evidence base for pneumonia prevention from 2015 onwards. His knowledge and

expertise in the area of epidemiology places him in high demand, nationally and internationally as a consultant. Dr. Levine's professional memberships affirm the relevancy of his special interests. Currently he is a Steering Committee Member of Johns Hopkins Vaccine Initiative (JHVI), Johns Hopkins Bloomberg School of Public Health and has authored over 75 peer-reviewed publications and book chapter.

Jaykumar Menon brings to the X PRIZE Foundation a long history as an award-winning international human rights lawyer. Working with the Center for Constitutional Rights and in conjunction with community activists and private investigators, Mr. Menon has represented the student leaders from Tiananmen Square against Li Peng, helped win a \$4 billion judgment on behalf of victims of the Bosnian genocide against Radovan Karadzic and represented the family of the late Nigerian environmental activist Ken Saro-Wiwa against Royal Dutch Shell. Mr. Menon has also represented several developing countries, including the Republic of South Africa and the head of state of a Caribbean nation, in their dealings with the international economic system.

Mr. Menon is a research fellow at the Centre for International Sustainable Development Law at McGill University and has written articles in many peer-reviewed international human rights law journals and reference books. Mr. Menon has also worked at McKinsey & Company and co-founded a venture-funded Internet company. He is a published creative writer, and served as associate editor of a book published by McSweeney's. Mr. Menon holds a Juris Doctor from Columbia Law School, a Master of International Affairs from the Columbia School of International and Public Affairs, and a Bachelor of Arts from Brown University. He hopes to creatively effect large-scale positive social change.

PANEL 3

Accounting for Global Health: Understanding Funding Opportunities

This panel will shed light on trends in global health funding and philanthropy. It will answer the questions: What funding is currently available? How do companies access it? In addition to direct funding, what other incentives are available for product development?

MODERATOR:

- Yves Ribeill, CEO, SCYNEXIS

PANELISTS:

- Erin Hogan, Vice President, Senior Philanthropic Advisor, JP Morgan
- Mary Moran, Director, Policy Cures
- Andrew S. Robertson, Chief Policy Officer, BIO Ventures for Global Health

WHO'S WHO

Erin Hogan, Vice President, serves as a senior philanthropic advisor for individuals, families, private foundations and charitable trust clients of J.P. Morgan Private Bank. Erin specializes in giving programs in the areas of health care, medical research, international relief, k-12 and higher education and social services.

Before joining J.P. Morgan, Erin was a research manager at Columbia University's Mailman School of Public Health where she supervised research programs in emergency preparedness, infectious disease control and occupational health and safety. Prior to that, Erin worked for a Washington, D.C. consulting firm on a variety of public health and environmental safety projects for government agencies such as the US Environmental Protection Agency and the Federal Emergency Management Agency.

Erin is a former paramedic and has volunteered with numerous public health and education organizations. She currently serves as the vice chair for the Donors' Education Collaborative of New York City and as an advisor for the GAVI Campaign. Erin is a member of Grantmakers in Health, Grantmakers for Education and the Alumni Board for the Mailman School of Public Health at Columbia University. Erin has a Masters of Public Health degree from Columbia University and a BS in Health Sciences from The George Washington University.

Mary Moran, Director of Policy Cures, has over 20 years experience in health policy and practice, including 10 years specialising in neglected disease policy. She has conducted projects for a wide range of public and multilateral health organisations with a focus on policy solutions for emerging issues related to neglected disease R&D. In 2004, Mary founded the research group that became Policy Cures at the London School of Economics & Political Science, later transferring it to the George Institute for International Health in Sydney.

Prior to forming the group, she worked for over a decade in Emergency Medicine; was a diplomat and policy analyst with the Australian Department of Foreign Affairs & Trade; Director of Medecins

Sans Frontieres Access to Essential Medicines Campaign in Australia; and a Europe-based policy advocate with MSF on issues relating to access to medicines for neglected patients. Dr. Moran is an Honorary Senior Lecturer at the London School of Hygiene and Tropical Medicine, and an Expert Adviser to the World Health Organisation, European Commission, European and Developing Countries Clinical Trials Partnership, Global Alliance for Vaccines and Immunisation (GAVI), OECD and the Wellcome Trust.

Yves Ribeill is the President & CEO of SCYNEXIS, Inc. Dr. Ribeill was the Director of Chemistry for Insecticide and Animal Health Research at Rhone-Poulenc Agricultural Products Company facility in Research Triangle Park, North Carolina. He held this position from January 1998 to July 1, 2000.

Before joining the agrochemical sector Dr. Ribeill held various positions during his 14 years in the pharmaceutical sector of Rhone-Poulenc including group leader in Discovery Chemistry for Antiviral Research and later in the Central Nervous System Group in France. He then became group leader in the Cardiovascular Group in England. Upon his return to France he was appointed Director of Chemistry for the Anti-Infective Group. Dr. Ribeill was involved in all phases of the drug discovery and development effort that culminated in the FDA approval of the antibacterial Synercid in 1999.

Dr. Ribeill received his PhD from the University of Montpellier (France) after conducting research on the development of new synthetic methodologies utilizing phosphorus compounds. He is the author of more than 26 publications and 12 patents. Dr. Ribeill is an expert-advisor to the French Government for drug research investment and member of the Medicines Malaria Venture Expert Scientific Advisory committee at the World Health Organization in Geneva. He is a member of the Royal Society of Chemistry in England and of the French Society of Chemistry.

Andrew S. Robertson joined BIO Ventures for Global Health (BVGH) as Chief Policy Officer in September 2010. He brings with him an expertise in innovation policy, and carries a diverse background centered on science policy and neglected disease research.

Before joining BVGH, Dr. Robertson was a graduate researcher at the University of California, Berkeley, where he focused on issues regarding synthetic biology, personalized medicine, and drug development within neglected disease markets. Prior to this, Dr. Robertson served as an International Health Officer and Science Advisor at the U.S. Department of Health and Human Services (HHS), Office of the Secretary. At HHS, his portfolio included issues concerning global health, biodefense, and biosecurity, with a particular focus on pandemic influenza. Dr. Robertson held a faculty research post at the Wellcome Trust Sanger Institute in Cambridge, UK, where he focused on immunology and protease inhibition.

In addition to his professional activities, Dr. Robertson is a Trustee of the Gates Cambridge Scholarship, serves as Co-Chair of the American Bar Association's Committee for the Rights and Responsibilities of Scientists, and was a AAAS Science & Technology Policy Fellow. He received his JD from the University of California, Berkeley, School of Law (Certificate in Science & Technology Law), and his PhD in genetics from the University of Cambridge, where he was a Gates Cambridge Scholar.

BREAKOUT SESSION 3A

How to Access Non-Traditional Financing

Following Panel 3, this breakout session will inform industry participants about where and how to access funding for neglected disease R&D. The session will be moderated by David Perry, CEO of Anacor Pharmaceuticals, who will ask the “hard questions” of government, foundation, and PDP funders about how to access the funding opportunities in this space.

MODERATOR:

- David Perry, CEO, Anacor Pharmaceuticals

PANELISTS:

- Michael Kurilla, Director, Division of Office of BioDefense Research Affairs, NIH/NIAID
- Robert C. Lorette, Senior Vice President, Business Development, Global Alliance for TB Drug Development
- John Schaetzl, Consultant to the Bill & Melinda Gates Foundation

WHO'S WHO

Michael Kurilla is the Director of the Office of Biodefense Research Affairs and Associate Director for Biodefense Product Development for the National Institute of Allergy and Infectious Diseases (NIAID). His primary role is to provide overall institute coordination for product development of medical countermeasures against bioterror threats. He received his undergraduate degree in chemistry from the California Institute of Technology. He earned his MD and PhD from Duke University. He took his postgraduate medical training in Pathology at the Brigham & Women's Hospital in Boston, MA and a postdoctoral fellowship with Dr. Elliott Kieff at Harvard Medical School as a Life Sciences Research Foundation Fellow followed by a Markey Scholar Award. At the University of Virginia, he was an Assistant Professor of Pathology as well as Co-Director of the Laboratory of Molecular Diagnostics and Associate Director for Clinical Microbiology. He moved to the private sector working in anti-infective drug development at Dupont Pharmaceuticals, Bristol-Myers Squibb, and Wyeth. He subsequently joined the National Institute of Allergy and Infectious Diseases (NIAID) as a Medical Officer. In 2005, he was named to his current positions within NIAID.

Robert C. Lorette, Esq. is Senior Vice President of Business Development for the TB Alliance. In this role, he helps lead the TB Alliance's efforts to establish agreements and strategic alliances within the context of the product development partnership (PDP) business model, and thus play an integral role in achieving the portfolio development and related resource mobilization goals of the TB Alliance.

Before joining the TB Alliance, Robert founded and was President and CEO of Boston Life Science Advisors, a corporate development consulting firm dedicated to serving biotech, medical device and other life science organizations. He also co-founded and served as Managing Director of Transform Ventures LLC, a firm that brings capital, executive leadership, and engineering and manufacturing resources together to rapidly advance medical device technologies to a significant value inflection point.

Before founding these two companies, Robert served as Chief Business Officer and Senior Vice President of Dynogen Pharmaceuticals, Inc., a clinical-stage drug development company focusing on gastrointestinal and genitourinary disorders. Earlier in his career, he served in various management, corporate development, and legal roles for organizations such as Boston Healthcare Associates, Inc., UroMed Corporation, and Bausch & Lomb Incorporated.

Robert received his law degree from Syracuse University College of Law and is admitted to practice law in Massachusetts, Connecticut, and New York. Additional accreditations include a Masters in Public Administration from the Maxwell School of Syracuse University and a Bachelor's degree in economics from the College of the Holy Cross. He also attended the Program for Management Development at the Harvard Business School.

David P. Perry has served as Anacor's President and Chief Executive Officer since March 2002 and has been a member of the board of directors since April 2002. In 1997, David founded Chemdex Corporation, which was acquired by NexPrise, Inc., a business-to-business marketplace company that focused on the life-sciences industry, and until November 2001 served as its Chief Executive Officer. In 1995, he co-founded Virogen, a biotech company based in Boston. He serves on the board of the Infectious Disease Research Institute, a nonprofit global health research center. David earned a BS from the University of Tulsa and an MBA from Harvard Business School.

John Schaetzl is an independent consultant health care investor, analyst and manager with broad and deep experience in several organizational settings. He is currently employed in several advisory roles. He is also the Lead Non-Executive Director at SustainAbility LTD, a global think tank and consultancy where he is responsible for monitoring fulfillment of SustainAbility's triple bottom line charter and hybrid structure.

In addition to advising the Bill & Melinda Gates Foundation, John advises other foundations and government agencies, as well as venture capital and institutional fund managers, on investments which support sustainable outcomes in global health access and economic development in emerging markets. He is on the Board of Columbus House Inc. and the Interim Board of the Oxford Lotus Health Fund. He has participated in four Phama Futures Workshops multi-year dialogs between pharmaceutical industry execs and institutional investors.

John retired from General Electric Asset Management after a decade of healthcare investing. Prior to that he was an executive with Bayer Pharmaceuticals, a consultant to the pharmaceutical industry and a University teacher and administrator. John is the co-author of Practical Politics and American Government (McMillan) and Project 18: Effectively Educating Young Voters (Edinboro).

BREAKOUT SESSION 3B

Strategies for Engaging Emerging Markets

Following Panel 3, in this breakout session panelists will discuss dual-market opportunities and viable commercialization strategies for partnering with emerging market manufacturers. High-level officials from emerging markets will provide practical guidance on navigating international regulatory requirements, relationships with international institutions, and the challenges of investing in emerging market companies.

MODERATOR:

- David Campbell, Principal, IMS Health

PANELISTS:

- Minister Lino Barañao, Minister of Science, Technology and Productive Innovation, Government of Argentina
- Maharaj K. Bhan, Secretary, Department of Biotechnology, Government of India
- G. Steven Burrill, CEO, Burrill & Company
- Bongsi Gumede, Senior General Manager, Technology Innovation and Marketing, Technology Innovation Agency, South Africa
- Julio Ramundo, Managing Director, Venture Capital, Environmental and Capital Markets Divisions, Brazilian Development Bank (BNDES)

WHO'S WHO

Lino Barañao Lino Barañao serves as the Minister of Science, Technology and Innovation of Argentina, an office created during the incumbent administration of Ms. Cristina Fernandez de Kirchner in 2007. Previously, Dr. Barañao acted as Chairman of the Board of Directors of the National Agency for the Promotion of Science, Technology and Innovation (ANPCyT).

Dr. Barañao is a trained scientist, and received his PhD in Chemical Sciences from the University of Buenos Aires, after which he spent time in Germany and the United States, where he held post-doctoral positions. He was appointed a fellowship at the National Research Council of Argentina (CONICET) and worked at the Institute of Experimental Biology and Medicine as Director of the Laboratory of Biotechnology for Animal Reproduction.

Dr. Barañao has received many awards for his research in animal technology and for his role as head of the ANPCyT and in the development of science in Argentina. His opinion columns have been published in a variety of major publications, and have focused on his leadership in shaping the path of Argentina as it becomes a leading global actor in the world of science and technology.

Maharaj K. Bhan serves as the Secretary of the Ministry of Science & Technology, Department of Biotechnology of India. He is recipient of numerous awards: "Shanti Swarup Bhatnagar Award", 1990, for medical sciences, the highest Scientific Award below 45 years of age in Indian Sciences, National Ranbaxy Award, 1990, for Medical Sciences, Achar Gold Medal of the Indian Academy of Pediatrics, 1984, for the best original research, S.S. Mishra Award of the National Academy of Medical Sciences,

1986, for the best unpublished research, Biotech Product and Process Development and Commercialization Award, 2003 and Pollins Foundation Research Award for US 100,000 (Year 2003).

Dr. Bhan is involved with policy formulation role as: Chairman, WHO Task Force on child health research, Member, Board of Directors, International Vaccine Institute, Korea, Chairman, National Task Force on micronutrient policy, Member, Technical Advisory Group, World Health Organization, Member, NIH Task Force on Rotavirus Vaccines, Chairman, Maternal and Child Health Research, Indian Council of Medical Research, Chairman, Scientific Advisory Committee, National Institute of Nutrition, India, Member of the Jury for nearly all major national science awards in India such as Shanti Swarup Bhatnagar Award, Birla Science Award and Ranbaxy National Award, Member, Science and Engineering Research Council, Department of Science and Technology, India, Member, Medical Biotechnology Board, Department of Biotechnology, Member, Technical Advisory Group, Child and Adolescent Health Division, World Health Organization, Geneva, Chairman, National Adaptation Committee, Integrated Management of Child Health, India, Member, Scientific Advisory Committee, Indian Council of Medical Research, Advisor to the Drug Regulatory Authority of India, Member, Scientific Advisory Committee, National Institute of Enteric Diseases and Cholera, India, Member, Program Advisory Committee on Medical Biology, Department of Science and Technology, India, Member, Immunization Advisory Board, Government of India. Member, Scientific Advisory Committee, Tuberculosis Research Centre, India, Member, Scientific Advisory Committee, National Institute of Epidemiology, India, Chairman, Committee for Preparation of Strategy for Promotion of neonatal health in South East Asia, SEARO.

Dr. Bhan holds the degrees of MBBS, MD Pediatrics, DSc (Honorary), and is a Fellow, Indian National Science Academy (FNA), Fellow, Academy of Sciences (FASc) and Fellow, Academy of Medical Sciences (FAMS).

G. Steven Burrill has been involved in the growth and prosperity of the biotechnology industry for over 40 years. An early pioneer, Steven is one of the original architects of the industry and one of its most avid and sustained developers. He currently serves as Chairman of the Board of Abunda Nutrition, Inc., and is a member of the boards of directors of Catalyst Biosciences, Depomed, NewBridge, Proventys, Targacept and XDx. Prior to founding Burrill & Company in 1994, he spent 28 years with Ernst & Young, directing and coordinating the firm's services to clients in the biotechnology/life sciences/high technology/ manufacturing industries worldwide. In 2002, Steven was recognized as a biotech investment visionary by the prestigious Scientific American Magazine (The Scientific American 50), as well as being honored at the American Liver Foundation's Annual "Salute to Excellence" Gala, which honors the best and the brightest from the Bay Area's medical, biotech and bio-pharmaceutical industries. In 2008 he received the BayBio Pantheon 2008 DiNA lifetime achievement award for his worldwide biotech leadership.

In addition to his work with leading life science companies, Steven is a founder and currently serves as Chairman of the Board of the Foundation for the National Medals of Science and Technology. Additionally, he serves as Chairman of the San Francisco Mayor's Biotech Advisory Committee (MAYBAC). He also chaired the National Research Council study on linkages in biotechnology between Japan and the United States and was involved with the US-Japan Science and Technology Agreement Study of Technology Transfer Mechanisms between the US and Japan. Other not-for-profit activities include serving on the boards of directors of the Bay Area Science Infrastructure Consortium, BayBio (Emeritus), California Healthcare Institute (Emeritus), The Exploratorium (Emeritus), The Kellogg Center for Biotechnology, the MIT Center for Biomedical Innovation, the

National Health Museum (Vice Chairman), World Council for Ethical Standards (Chairman), Vilas County Economic Development Group (Chairman), BIO Ventures for Global Health (BVGH), University of Wisconsin Extension, and the Scientific American Board of Advisors. He also serves on the editorial board of the Journal of Commercial Biotechnology and is on the advisory boards of the Center for Policy on Emerging Technologies (C-PET), as well as BioAg Gateway, City of Madison. He is an advisor to University of Illinois Institute for Genomic Biology, University of Wisconsin—College of Agriculture and Life Sciences, University of Minnesota College of Biological Sciences, and Duke University, and is an adjunct professor at University of California, San Francisco.

David Campbell is a Senior Principal in Strategy and Portfolio Analysis for IMS Health. Based in the London office, he also serves as Global Leader of IMS's Emerging Markets Platform. He has over 10 years of extensive experience in the pharmaceutical and consulting industry in the US and Europe.

Prior to joining IMS, David was a Consulting Partner at Catenion Strategies, a boutique strategy consulting firm based in Berlin. At Catenion he led numerous engagements including a post merger development portfolio review for a major pharmaceutical organization, helping a new entrant into the oncology market to define the late stage development programme for a key brand that has now become a major player in the oncology space, and a number of corporate strategy initiatives.

David graduated from Strathclyde University with a degree in Immunology and Pharmacology in 1991 and from there studied for the degree of PhD at Glasgow University where his thesis was on the topic of genetics of colorectal cancer. Having graduated from Glasgow he then spent five years at the University of Leeds where he led a genetic research group interested in defining the genetic basis of a number of disorders such as Asthma, Developmental Disorders and Anorexia Nervosa.

From Leeds, David went to SmithKline Beecham where he was a Group Leader in Genetic Technologies before taking on the role of Director of Molecular Genetics Europe in the combined GSK organization. Towards the end of his tenure at GSK he was seconded into Portfolio Management where he led a team of individuals responsible for reviewing and rationalizing the Genetics Research Portfolio.

David then left GSK in 2004 and became CSO for a small VC funded company called Etiologics. He was part of the senior management team who led the purchase of Bayer's preclinical respiratory capability before helping Etiologics initiate a reverse take-over of Argenta Discovery.

Having left Etiologics at the beginning of 2005, David then spent 12 months working as an external consultant with AstraZeneca helping them define their Discovery Medicine strategy for oncology.

Bongi Gumede is the Senior General Manager for Marketing and Technology Innovation in the Technology Innovation Agency of South Africa. The Technology Innovation Agency (TIA) was established by the South African government to stimulate and intensify technological innovation in order to improve economic growth and the quality of life of all South Africans by developing and exploiting technological innovations. The Agency is set up as a public entity with the aim to enhance the country's capacity to translate a greater proportion of local research and development into commercial technology products and services.

He is responsible for overseeing and driving TIA's Business Development and Marketing Services to relevant stakeholders to support the Regional Technology Innovation strategies. The responsibilities include management of the implementation of the Regional Technology Innovation strategies and expand TIA's footprints across all the Provinces of South Africa.

Previously he was the Executive Health Portfolio Manager for Biotechnology Partnerships and Development (BioPAD). His main tasks included developing and managing a balanced strategy for Human and Animal Health Portfolio for BioPAD. He was heavily involved with raising global funds especially for research and development in animal and human disease areas relevant to South Africa. He also managed the establishment of a Pre-clinical drug development platform for South Africa, an initiative of the South African government through Department of Science and Technology. He was also appointed Competency Area Manager for Drug and Therapeutic Discovery within CSIR Biosciences, to managing and overseeing the drug discovery activities contained in the Bio-prospecting, Aptamer, Structural Biology, Systems Biology, Discovery Chemistry and Analytical Chemistry research groups within CSIR Biosciences. The main objective of this position was to be able to raise local and global funds for R&D activities in HIV, Malaria and Tuberculosis.

Dr. Gumede has 11 years of international experience in the research and development environment and the private sector. Dr. Gumede developed strategic partnerships with numerous key stakeholders and this has made him very conversant with national systems of innovation, particularly in Africa. Dr Gumede holds a Doctor of Philosophy degree in Pharmacology from the University of Cape Town, South Africa. His achievements include the award of the prestigious John Sainsbury/Linbury Trust Doctoral Fellowship to study part of his PhD at Oxford University, UK. He has attended the Executive Development Programme at University of Stellenbosch and has published in reputable journals and presented at international conferences.

Julio Ramundo has served as Deputy Managing Director of the industrial division of the Brazilian Development Bank (BNDES) since 2008, where he began his career as a result of BNDES' public selection process in 1992. Julio has since held various executive positions at the institution, including head of the department of trade and services, head of the department of electronic industry and Deputy Managing Director of the social inclusion division. Mr. Ramundo has also served as chairman of the board of directors of the BNDES Social Assistance and Welfare Foundation (Fundação de Assistência e Presidência Social), or FAPES, and as a member of the board of directors of Padtec SA. Mr. Ramundo has represented BNDES on the governing councils of various organizations and companies, including Sociedade Softex, and the Information Technology Committee of the Brazilian Ministry of Science and Technology (Comitê de Informática do Ministério de Ciência e Tecnologia). He served as a Director at Tele Norte Leste Participacoes SA since April 2010. Mr. Ramundo holds a bachelor's degree in economics from Universidade Federal do Rio de Janeiro and completed the requirements for a master's degree in economics from the Graduate School of Economics at Fundação Getúlio Vargas (EPGE/FGV). Mr. Ramundo also holds an MBA with Distinction from the London Business School at the University of London.

KEYNOTE ADDRESS

Francis Collins, Director, National Institutes of Health

Dr. Francis Collins will share his insights on how ground-breaking biotech innovations can serve the health needs of the world's poorest. He oversees the work of the largest supporter of biomedical research in the world, spanning the spectrum from basic to clinical research. He is a physician-geneticist noted for his landmark discoveries of disease genes and his leadership of the international Human Genome Project.

WHO'S WHO

Francis S. Collins, MD, PhD, is the Director of the National Institutes of Health (NIH). In that role he oversees the work of the largest supporter of biomedical research in the world, spanning the spectrum from basic to clinical research.

Dr. Collins, a physician-geneticist noted for his landmark discoveries of disease genes and his leadership of the international Human Genome Project, served as director of the National Human Genome Research Institute (NHGRI) at the NIH from 1993-2008. The Human Genome Project culminated in April 2003 with the completion of a finished sequence of the human DNA instruction book.

Dr. Collins' own research laboratory has discovered a number of important genes, including those responsible for cystic fibrosis, neurofibromatosis, Huntington's disease, a familial endocrine cancer syndrome, and most recently, genes for type 2 diabetes and the gene that causes Hutchinson-Gilford progeria syndrome, a rare cause of premature aging.

Dr. Collins received a BS in chemistry from the University of Virginia, a PhD in physical chemistry from Yale University, and an MD with honors from the University of North Carolina at Chapel Hill. Prior to coming to the NIH in 1993, he spent nine years on the faculty of the University of Michigan, where he was a Howard Hughes Medical Institute investigator. He is an elected member of the Institute of Medicine and the National Academy of Sciences. Dr. Collins was awarded the Presidential Medal of Freedom in November 2007 and the National Medal of Science in 2009.

UPCOMING BIO EVENTS

***Bio* India International Partnering Conference**

September 21–22, 2011 | Hyderabad, India

***Bio* China International Conference**

October 12–13, 2011 | Shanghai, China

***Bio* Investor Forum**

October 25–26, 2011 | San Francisco

***Bio*-Europe® International Partnering Conference**

October 31–November 2, 2011 | Düsseldorf, Germany

***Bio* Asia International Partnering Conference**

January 2012* | Osaka, Japan

***Bio* CEO & Investor Conference**

February 13–14, 2012 | New York City

***Bio*-Europe® Spring International Partnering Conference**

March 19–21, 2012 | Amsterdam, Holland

***Bio* Business Forum™ at the BIO International Convention**

June 18–21, 2012 | Boston, MA

Partnering for Global Health Forum

June 18, 2012 | Boston, MA

* Specific dates to be announced

NOTES